Oslo, 13 December 2019, Ultimovacs announces that the universal cancer vaccine UV1 will be investigated in a randomized, multi-center phase II trial in mesothelioma. The trial, named NIPU, investigates UV1 in combination with the checkpoint inhibitors nivolumab and ipilimumab as second-line treatment in mesothelioma. Oslo University Hospital (‘OUS’) is the sponsor of the study. Bristol-Myers Squibb (‘BMS’) and Ultimovacs have entered into agreements with OUS to support the preparations and execution of the trial. A total of 118 patients will be included in the study. Half of the patients will be treated with the combination of UV1, nivolumab and ipilimumab, whereas the other half will receive nivolumab and ipilimumab only.
With support from Bristol-Myers Squibb and Ultimovacs, UV1 will be tested in a large, randomized combination trial in mesothelioma initiated by Oslo University Hospital
News
Ultimovacs held its presentation of the company’s Q3-19 report on 14 November 2019 at Oslo Cancer Cluster Innovation Park. The report and presentation is available in the “Reports and presentation” section.
Technology
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Clinical studies
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.